Albumin News and Research

RSS

“Sybodies” protect against SARS-CoV-2 in hamster model

Researchers in China, The Netherlands, France, and Switzerland have identified synthetic nanobodies or “sybodies” that exhibit potent neutralizing activity against severe acute respiratory syndrome coronavirus (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic.

3 Aug 2021

New technology can pave the way for development of long-acting drugs

The technology, consisting of a designed variant of a natural occurring protein called super albumin, can pave the way for the development of long-acting drugs. This can have major implications for individuals suffering from hemophilia.

21 Jul 2021

A pencil graphite biosensor that detects SARS-CoV-2

In a new study, scientists discuss the development of a rapid COVID-19 diagnostic tool known as the Low-cost Electrochemical Advanced Diagnostic (LEAD).

14 Jul 2021

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Scientists from the US and Germany have recently evaluated the efficacy of an mRNA-based COVID-19 vaccine candidate, CV07050101, in inducing humoral and cellular immune responses in non-human primates. The study reveals that prime-boost immunization with the vaccine candidate induces only limited immunity against SARS-CoV-2.

12 Jul 2021

New practice guideline includes recommendations for reducing blood loss during heart surgery

Four leading medical specialty societies released a new clinical practice guideline today that includes recommendations for reducing blood loss during heart surgery and improving patient outcomes.

1 Jul 2021

Albumin supplementation improves human fertility, fights infection

A new University of California, Irvine-led study reveals albumin (Alb), among the most abundant proteins in the body, activates a proton channel (hHv1), also widespread in the body, giving sperm the ability to penetrate and fertilize an egg, and allowing white blood cells to secrete large amounts of inflammatory mediators to fight infection.

22 Jun 2021

Multivalent antibodies show high potency against SARS-CoV-2 in new study

A new study in the journal Nature Communications describes the process of converting a SARS-CoV-2 antibody into a multivalent form, thus enabling it to bind at various different points with its epitope.

21 Jun 2021

Vaccination against SARS-CoV-2 with a single dose skin patch

Researchers from Australia recently reported a high-density microarray patch used to deliver a SARS-CoV-2 spike subunit vaccine to the skin directly. They used a combination of a SARS-CoV-2 spike protein vaccine candidate and the high-density microarray patch (HD-MAP) vaccine delivery platform.

7 Jun 2021

Researchers identify defensins as potential anti-SARS-CoV-2 agents

A recent study conducted at the Ohio State University, USA, and the Fudan University, China, has revealed that alpha-defensin human neutrophil peptide 1 (HNP1), a cationic antimicrobial peptide, can prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from infecting cells by destabilizing the viral spike protein and disrupting spike-mediated viral envelop – host cell membrane fusion.

31 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years. In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death.

From AstraZeneca 14 May 2021

New strategy could increase the effectiveness of chemotherapy treatments

New research led by a team at Massachusetts General Hospital (MGH) points to a promising strategy to boost tumors' intake of cancer drugs, thereby increasing the effectiveness of chemotherapy treatments.

7 May 2021

Albumedix extends research collaboration with Cobra Biologics to optimize viral vector manufacturing

Albumedix Ltd. ('Albumedix'), an emerging leader in the enablement of advanced therapies and recognized global leader in recombinant human albumin (rHA) has today announced an extension to its research collaboration with Cobra Biologics, the gene therapy division of Cognate BioServices, a Charles River Laboratories International, Inc. company.

From Albumedix Ltd. 28 Apr 2021

Researchers probe intriguing interaction between sugars and the SARS-CoV-2 spike protein

A new study posted to the bioRxiv preprint server focuses on a novel formulation of magnetization or saturation transfer. This method is developed by amalgamating theoretical and computational approaches based on a Bayesian deconvolution algorithm, which helps obtain data more accurately and determine the ligand-protein interaction.

16 Apr 2021

Albumedix Expands Production Capacity at its Commercial-Scale Recombinant Human Albumin Manufacturing Plant and Opens New Research Facilities

Albumedix Ltd. ('Albumedix'), a recognized global leader in recombinant human albumin specializing in the enablement of advanced therapies, announces the completed expansion of the company’s commercial-scale manufacturing facility, alongside with the establishment of a new Technology Centre equipped with state-of-the-art laboratories at its UK-based campus in Nottingham.

From Albumedix Ltd. 13 Apr 2021

Adequate levels of antioxidants may reduce HPV infection linked to cervical cancer development

A study led by Hui-Yi Lin, Ph.D., Professor of Biostatistics, and a team of researchers at LSU Health New Orleans Schools of Public Health and Medicine has found that adequate levels of five antioxidants may reduce infection with the strains of the human papillomavirus (HPV) associated with cervical cancer development.

13 Apr 2021

Vaccine-induced 2C08 antibody protects against SARS-CoV-2 variants

A new preprint study posted to the bioRxiv* server led by Ali H. Ellebedy from the Washington University School of Medicine found that the monoclonal antibody 2C08 produced by the Pfizer vaccine could help neutralize COVID-19 variants.

29 Mar 2021

Corticosteroid therapy in pregnant women with COVID-19

A new study describes the outcome of corticosteroid use in pregnancy.

29 Mar 2021

Researchers develop novel nanoadjuvant COVID-19 vaccine candidate

Researchers at the National Center for Nanoscience and Technology of China, the Chinese Academy of Sciences (CAS), introduced a new vaccine, which compromises the spike protein’s receptor-binding domain (RBD) and the manganese nanoadjuvant (MnARK), inducing humoral and cellular responses.

29 Mar 2021

Albumedix announces recombinant human albumin supply partnership with FUJIFILM Wako Pure Chemical Corporation for the Japanese, Chinese and Hong Kong markets

Albumedix Ltd. (‘Albumedix’), an enabler of advanced therapies and world leader in recombinant human albumin (rHA), announced today that they have entered into a distribution agreement with established and well recognized reagent supplier FUJIFILM Wako Pure Chemical Corporation (FUJIFILM Wako) in Japan and China including Hong Kong.

From Albumedix Ltd. 29 Mar 2021

Albumin News and Research

“Sybodies” protect against SARS-CoV-2 in hamster model

New technology can pave the way for development of long-acting drugs

A pencil graphite biosensor that detects SARS-CoV-2

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

New practice guideline includes recommendations for reducing blood loss during heart surgery

Albumin supplementation improves human fertility, fights infection

Multivalent antibodies show high potency against SARS-CoV-2 in new study

Vaccination against SARS-CoV-2 with a single dose skin patch

Researchers identify defensins as potential anti-SARS-CoV-2 agents

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

New strategy could increase the effectiveness of chemotherapy treatments

Albumedix extends research collaboration with Cobra Biologics to optimize viral vector manufacturing

Researchers probe intriguing interaction between sugars and the SARS-CoV-2 spike protein

Albumedix Expands Production Capacity at its Commercial-Scale Recombinant Human Albumin Manufacturing Plant and Opens New Research Facilities

Adequate levels of antioxidants may reduce HPV infection linked to cervical cancer development

Vaccine-induced 2C08 antibody protects against SARS-CoV-2 variants

Corticosteroid therapy in pregnant women with COVID-19

Researchers develop novel nanoadjuvant COVID-19 vaccine candidate

Albumedix announces recombinant human albumin supply partnership with FUJIFILM Wako Pure Chemical Corporation for the Japanese, Chinese and Hong Kong markets

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest News